SpectraMedix AI-Driven Technology Powers Life-Saving Results in Opioid Overdose Prevention Program 

Staten Island PPS achieves 77% reduction in fatal overdoses

East Windsor, NJ—March 26, 2025—In the face of a deepening opioid crisis, Staten Island Performing Provider System (PPS) has made a substantial impact in overdose prevention: a 77% reduction in fatal overdoses through its Hotspotting initiative, powered by SpectraMedix technology. This program uses an AI-powered opioid harm prediction model—developed in collaboration with the Staten Island PPS team and the Massachusetts Institute of Technology (MIT) and further enhanced by SpectraMedix—to identify individuals at highest risk and enable earlier, more targeted interventions.

Over the program’s second year, Staten Island PPS achieved a 77% reduction in fatal overdoses, a 36% reduction in non-fatal overdoses, and a 63% reduction in emergency room visits related to substance use disorder among individuals engaged in the program. These outcomes reflect the impact of integrating predictive technology with timely action—providing the insight needed to intervene earlier, reduce avoidable utilization, and improve outcomes.

“SpectraMedix technology gives us the insight to proactively reach individuals before risk turns into crisis,” said Joseph Conte, Executive Director of Staten Island PPS. “With timely and targeted risk prediction, the platform generates actionable insights that guide our care teams to those who need support most—while there’s still time to change the outcome.”

The model predicts risk at the member level up to six months in advance, using advanced algorithms based on clinical and claims data, diagnostic codes, prescription patterns, and other key indicators. The SpectraMedix platform then translates these predictions into clear, actionable guidance—showing care teams exactly who is at highest risk and what actions to take so they can prioritize outreach, tailor interventions, and deliver timely support to vulnerable populations.

“This program demonstrates how predictive risk models can be operationalized in the real world—not just to anticipate risk but to drive specific action,” said Raj Lakhanpal, MD and CEO of SpectraMedix. “Our technology turns data into direction—equipping care teams to focus their efforts, engage earlier, and act where it’s needed most. Staten Island PPS has shown how these insights can be put to work to deliver real results.”

Building on its success, Staten Island PPS is expanding the Hotspotting initiative to more communities across New York City, while also establishing a national advisory model to help other regions combat the opioid crisis. The program aims to serve as a replicable, evidence-based model for overdose prevention— powered by predictive technology that identifies high-risk individuals, informs care coordination, and supports targeted, community-based intervention.

For more information on the Staten Island PPS Hotspotting Program, visit hotspottingtheoverdoseepidemic.com. For more information on how SpectraMedix drives value-based contract success, visit www.spectramedix.com/why-spectramedix.  

 

About SpectraMedix

SpectraMedix delivers the complete picture of value-based performance to drive operational excellence and accelerate performance improvement for health plans and health systems across the spectrum of value-based contracts. Our comprehensive, end-to-end platform empowers organizations with transparency into financial performance, quality, risk and utilization to help them establish trust with providers, maximize revenue and scale their value-based arrangements. For more information, visit www.spectramedix.com.

 

About Staten Island Performing Provider System (SI PPS)

The Staten Island Performing Provider System (SI PPS) is the lead Social Care Network for Richmond County. We are an integrated network of medical, behavioral, academic partners, and social service agencies. SI PPS aims to improve the quality of care, reduce costs, and improve health outcomes for Staten Island’s Medicaid and uninsured populations. Originally formed under the DSRIP program, SI PPS continues to refine its transformative work to reduce health disparities, enhance population health outcomes, and improve health equity. Learn more at www.statenislandpps.org

 

Contact Information

Nathan Brown 
Director of Marketing 
nathan.brown@spectramedix.com  
(609) 638-2987